Stargardt Disease Therapeutics Market Size, Share and Global Market Forecast to 2029 | DataMIntelligence

DataM Intelligence
The Global Stargardt Disease Therapeutics Market is expected to grow at a high CAGR of 31.5% during the forecasting period (2022-2029).

Market Dynamics

Research advances in stargardt disease are expected to drive the growth of the market

According to the article, on April 16, 2021. Emixustat, an oral drug that basically targeted the dry form of age-related macular degeneration (AMD), is conducting a Phase 3 clinical trial for Stargardt disease. While the drug did not meet desired outcomes in the AMD clinical trial, experts believe it may work well for people with Stargardt disease. The biotech company Alkeus conducts a multi-center Phase II clinical trial for a drug (ALK-001) that targets the toxic build-up in the retina that is thought to cause degeneration and vision loss. The emerging therapy is a modified form of vitamin A, which results in much less waste when metabolized in the retina. Scientists developed ALK-001 by replacing hydrogen atoms in vitamin A with deuterium. Known as deuterated vitamin A, it “burns cleaner” than the natural form. Deuterium is a safe, naturally occurring, stable form of hydrogen present in the human body.


Download free sample @


Market Segmentation – By Drug Type

LBS-008 is developed by Belite Bio which a subsidiary of Lin BioScience. It is a first-in-class oral therapy targeting Dry Age-Related Macular Degeneration (Dry AMD) and Stargardt Disease (Stargardt), which are eye diseases that cause vision loss in adults and children respectively and currently have no available treatment.

In June 2019, Acucela Inc., subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. announced that the European Medicines Agency (EMA) granted orphan designation to Acucela’s leading drug candidate emixustat hydrochloride for the treatment of Stargardt disease. The orphan designation does not apply to other indications for which emixustat is being developed

Market Segmentation – Region – North America

North America is dominating the stargardt disease therapeutics market and expected to account for the largest revenue share in 2020. The high share is attributed to the increasing number of product launches and approvals associated with Stargardt disease therapeutics by regulatory bodies; the increasing prevalence of Stargardt disease is expected to boost the market growth in the forecast period. According to the National Institute for Health, the reported prevalence of Stargardt disease is estimated to be 1 in 8,000 to 10,000 individuals.

In addition, according to the Foundation Fighting Blindness, Stargardt disease is the most common form of acquired macular degeneration, affecting about 30,000 people in the U.S. The increasing vision loss associated with Stargardt disease is affected by the degeneration of photoreceptor cells in the central portion of the retina called the macula.


Companies Growth Analysis

Market players are focusing on various growth plans such as agreements and acquisitions to expedite the development of treatment for Stargardt disease, which is expected to boost the market’s growth during the forecast period. For instance, on January 11, 2021, Aker BioMarine, a fishing and biotech company, entered into an agreement with Dr. Michael Davidson, a biotech entrepreneur, to develop pharmaceutical therapies for diseases associated with the brain and eye, such as Alzheimer’s Disease, dry age-related macular degeneration, and Stargardt’s juvenile blindness, by using LYSOVETA, a process established by the biotech company, Aker BioMarine for production of lysophosphatidylcholine (LPC)-bound EPA (eicosapentaenoic acid)/DHA (docosahexaenoic acid) from krill


View full report


Competitive Landscape

The major players are adopting several growth strategies such as product development, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance,

On July 14th 2021, Alkeus Pharmaceuticals, Inc., a private, late-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ALK-001 for the treatment of Stargardt Disease. ALK-001 (C20-D3-vitamin A) is a chemically- modified form of vitamin A developed to treat multiple retinal degenerative diseases.


Trending Topic’s

RNAi Therapeutics Market

Eczema Therapeutics Market

Media Contact
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States